We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+24.32%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$831M
AUM Growth
-$107M
Cap. Flow
-$210M
Cap. Flow %
-25.25%
Top 10 Hldgs %
81.97%
Holding
43
New
8
Increased
4
Reduced
13
Closed
11

Top Buys

Rank Stock Value
1
TNDM icon
Tandem Diabetes Care
TNDM
+$87.3M
2
GMED icon
Globus Medical
GMED
+$36M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$31M
4
LEGN icon
Legend Biotech
LEGN
+$25.5M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$24.3M

Top Sells

Rank Stock Value
1
MGNX icon
MacroGenics
MGNX
+$78.7M
2
UTHR icon
United Therapeutics
UTHR
+$76M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$43.7M
4
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$42.6M
5
ARVN icon
Arvinas
ARVN
+$30.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.32%
2 Financials 1.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
1
Protagonist Therapeutics
PTGX
$8.75B
$155M 18.62%
3,446,874
+737,165
+27% +$24.3M
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
$98.8M 11.89%
1,199,339
-2,060
-0.2% -$156K
TNDM icon
3
Tandem Diabetes Care
TNDM
$1.17B
$95.4M 11.48%
+979,226
New +$87.3M
GMED icon
4
Globus Medical
GMED
$10.4B
$84.1M 10.12%
1,084,979
+506,608
+88% +$36M
LEGN icon
5
Legend Biotech
LEGN
$4.3B
$67.6M 8.14%
1,647,497
+750,889
+84% +$25.5M
VSTM icon
6
Verastem
VSTM
$532M
$55.4M 6.66%
1,133,335
+199,884
+21% +$8.33M
KROS icon
7
Keros Therapeutics
KROS
$199M
$37.7M 4.54%
887,885
-2,324
-0.3% -$126K
SRPT icon
8
Sarepta Therapeutics
SRPT
$1.66B
$31.8M 3.83%
+409,301
New +$31M
UTHR icon
9
United Therapeutics
UTHR
$26.3B
$28.5M 3.44%
159,087
-399,075
-71% -$76M
AFMD
10
DELISTED
Affimed
AFMD
$27M 3.25%
317,642
-283,255
-47% -$25.8M
GMDA
11
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$18.3M 2.21%
2,858,558
-459,649
-14% -$3.17M
CASI
12
DELISTED
CASI Pharmaceuticals
CASI
$16M 1.93%
1,032,196
-21,876
-2% -$368K
CFMS
13
DELISTED
Conformis, Inc. Common Stock
CFMS
$14.7M 1.76%
509,761
-10,239
-2% -$242K
DCPH
14
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$14.2M 1.71%
388,222
-605,690
-61% -$23.5M
NKTX icon
15
Nkarta
NKTX
$162M
$13.9M 1.68%
439,876
-130,379
-23% -$3.76M
INFI
16
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$11.3M 1.36%
3,766,817
-2,808,183
-43% -$8.88M
ACET icon
17
Adicet Bio
ACET
$72.8M
$10.6M 1.27%
64,088
-11,966
-16% -$2.44M
CHFW.U
18
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
$10.4M 1.25%
1,000,000
– –
SIOX
19
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$8.11M 0.98%
2,969,987
-216,348
-7% -$538K
SLN
20
Silence Therapeutics
SLN
$521M
$5.78M 0.7%
222,222
– –
CLRB icon
21
Cellectar Biosciences
CLRB
$19.3M
$4.66M 0.56%
13,043
-537
-4% -$233K
RACB
22
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$3.03M 0.36%
300,000
– –
JYAC
23
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.98M 0.36%
300,000
– –
MSAC
24
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$2.9M 0.35%
+300,000
New +$2.93M
CMAX
25
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$2.75M 0.33%
+7,101
New +$2.82M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Consonance Capital Management held 43 positions worth $831M, down 11% from $938M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Consonance Capital Management withdrew a net $210M in Q2 2021, closing 11 positions and reducing 13 holdings. Its most notable exit was MacroGenics, an estimated $78.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Financials.

Against the trend, Consonance Capital Management opened a new position in Tandem Diabetes Care worth $95.4M.

  • Consonance Capital Management's largest Q2 2021 buy was Tandem Diabetes Care: 979,226 shares worth $95.4M.
  • Consonance Capital Management added most to Globus Medical in Q2 2021, an estimated $36M increase.
  • Consonance Capital Management's biggest Q2 2021 reduction was United Therapeutics, cutting an estimated $76M.
  • Consonance Capital Management fully exited MacroGenics in Q2 2021, selling an estimated $78.7M.
  • Consonance Capital Management's ten largest holdings make up 82% of its $831M portfolio in Q2 2021.
  • Consonance Capital Management opened 8 new positions and closed 11 in Q2 2021.
  • Consonance Capital Management's portfolio value fell 11% quarter-over-quarter to $831M.

Based on Consonance Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.